Er-Kim says Poland approved reimbursement for LOQTORZI

Er-Kim said Poland’s Ministry of Health added LOQTORZI (toripalimab) to its July 1 reimbursement list, giving funded access to patients with nasopharyngeal carcinoma and advanced esophageal squamous cell carcinoma. The listing expands treatment access for two hard-to-treat cancers in Poland and adds momentum to Er-Kim’s partnership with LEO Pharma.

Why it matters: - The reimbursement listing gives patients in Poland funded access to LOQTORZI for two difficult cancers with limited treatment options. - The decision covers nasopharyngeal carcinoma and advanced, recurrent or metastatic esophageal squamous cell carcinoma that cannot be removed by surgery. - Expanded reimbursement can reduce access barriers for rare oncology patients in Central and Eastern Europe.

What happened: - Er-Kim announced that Poland’s Ministry of Health included LOQTORZI (toripalimab) on the July 1 reimbursement list. - The listing applies in Poland and took effect through the national reimbursement framework. - The Ministry of Health’s July 1 list introduced 25 new therapies to the Polish market.

The details: - LOQTORZI is being funded for patients with nasopharyngeal carcinoma, a rare and aggressive head and neck cancer. - LOQTORZI is also funded for patients with advanced, recurrent or metastatic esophageal squamous cell carcinoma that is not operable. - Er-Kim said the listing reflects the operational strength of its alliance with LEO Pharma A/S. - Er-Kim said the partnership combines regulatory, market access and commercial expertise to address care gaps across Central and Eastern Europe. - In 2025, LEO Pharma A/S received exclusive distribution and sales rights for LOQTORZI in the European Union, the European Economic Area, Switzerland and the United Kingdom. - TopAlliance Biosciences remains the Marketing Authorisation Holder for LOQTORZI. - Er-Kim said the company was established in 1981 and works with more than 40 global partners. - Er-Kim said it distributes more than 68 products to 50+ countries and employs more than 400 professionals worldwide. - Er-Kim said annual revenue exceeds EUR 390M. - The company listed more information on its website. - The press release also pointed to Er-Kim’s LinkedIn page.

Between the lines: - The reimbursement decision signals continued payor interest in specialty oncology drugs for small patient populations. - The partnership framing suggests Er-Kim and LEO Pharma are using market access capabilities as a competitive lever in Europe. - The focus on rare and ultra-rare diseases in the Polish list fits a broader push toward targeted oncology coverage.

What’s next: - Patients and providers in Poland can now seek funded access to LOQTORZI under the national reimbursement system. - Er-Kim and LEO Pharma are likely to use the listing as a reference point for additional market access progress in the region. - The broader commercial impact will depend on how quickly the funded treatment reaches eligible patients and treatment centers.

The bottom line: - Poland’s reimbursement move opens a new funded pathway for LOQTORZI in two hard-to-treat cancers and strengthens Er-Kim’s regional commercialization position.